Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication

Journal of Virology

Volumn 83, Issue 5, 2009, Pages 2099-2108

  Teale, Alastair ^a   Campbell, Stephanie ^a   Van Buuren, Nick ^a   Magee, Wendy C ^a   Watmough, Kelly ^a   Couturier, Brianne ^a   Shipclark, Robyn ^a   Barry, Michele ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BIOGENOVA; BORTEZOMIB; CYTARABINE; LACTACYSTIN; MG 115; MG115 INHIBITOR; PROTEASOME; PROTEASOME INHIBITOR; PYR 41; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VIRUS DNA; PROTEINASE INHIBITOR; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DNA REPLICATION; DRUG ACTIVITY; DRUG EFFECT; ENZYME INHIBITION; EXPERIMENTAL INFECTION; FEMALE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; ORTHOPOXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UBIQUITINATION; VIRUS GENE; VIRUS REPLICATION; ANIMAL; CERCOPITHECUS; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HAMSTER; METABOLISM; PHYSIOLOGY;

POXVIRIDAE;

ANIMALS; CERCOPITHECUS AETHIOPS; CRICETINAE; DNA REPLICATION; DNA, VIRAL; HELA CELLS; HUMANS; MICE; ORTHOPOXVIRUS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; UBIQUITIN-ACTIVATING ENZYMES; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 60049095589     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01753-08     Document Type: Article

References (72)

1. Afonso, C. L., E. R. Tulman, Z. Lu, L. Zsak, G. F. Kutish, and D. L. Rock. 2000. The genome of fowlpox virus. J. Virol. 74:3815-3831.
2. Andrei, G., D. B. Gammon, P. Fiten, E. De Clercq, G. Opdenakker, R. Snoeck, and D. H. Evans. 2006. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 80:9391-9401.
3. Babiuk, L. A., B. Meldrum, V. S. Gupta, and B. T. Rouse. 1975. Comparison of the antiviral effects of 5-methoxymethyl-deoxyuridine with 5-iodode- oxyuridine, cytosine arabinoside, and adenine arabinoside. Antimicrob. Agents Chemother. 8:643-650.
4. Banks, L., D. Pim, and M. Thomas. 2003. Viruses and the 26S proteasome: hacking into destruction. Trends Biochem. Sci. 28:452-459.
5. Barry, M., and K. Fruh. 2006. Viral modulators of cullin RING ubiquitin ligases: culling the host defense. Sci. STKE 2006:pe21.
6. + T lymphocytes. J. Virol. 69:5243-5251.
7. Buller, R. M., G. Owens, J. Schriewer, L. Melman, J. R. Beadle, and K. Y. Hostetler. 2004. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318:474-481.
8. Byrd, C. M., T. C. Bolken, A. M. Mjalli, M. N. Arimilli, R. C. Andrews, R. Rothlein, T. Andrea, M. Rao, K L. Owens, and D. E. Hruby. 2004. New class of orthopoxvirus antiviral drugs that block viral maturation. J. Virol. 78: 12147-12156.
9. Chen, Y. T., C. H. Lin, W. T. Ji, S. K. Li, and H. J. Liu. 2008. Proteasome inhibition reduces avian reovirus replication and apoptosis induction in cultured cells. J. Virol. Methods 151:95-100.
10. Chung, C. S., C. H. Chen, M. Y. Ho, C. Y. Huang, C. L. Liao, and W. Chang. 2006. Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J. Virol. 80:2127-2140.
11. Cuconati, A., C. Mukherjee, D. Perez, and E. White. 2003. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 17:2922-2932.
12. De Clercq, E., E. Darzynkiewicz, and D. Shugar. 1975. Antiviral activity of O'-alkylated derivatives of cytosine arabinoside. Biochem. Pharmacol. 24: 523-527.
13. Delboy, M. G., D. G. Roller, and A. V. Nicola. 2008. Cellular proteasome activity facilitates herpes simplex virus entry at a postpenetration step. J. Virol. 82:3381-3390.
14. Demartino, G. N., and T. G. Gillette. 2007. Proteasomes: machines for all reasons. Cell 129:659-662.
15. Deng, L., P. Dai, A. Ciro, D. F. Smee, H. Djaballah, and S. Shuman. 2007. Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J. Virol. 81:13392-13402.
16. Domi, A., and G. Beaud. 2000. The punctate sites of accumulation of vaccinia virus early proteins are precursors of sites of viral DNA synthesis. J. Gen.Virol. 81:1231-1235.
17. Engelstad, M., and G. L. Smith. 1993. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194:627-637.
18. Forster, A., and C. P. Hill. 2003. Proteasome degradation: enter the substrate. Trends Cell Biol. 13:550-553.
19. Guerin, J. L., J. Gelfi, S. Boullier, M. Delverdier, F. A. Bellanger, S. Bertagnoli, I. Drexler, G. Sutter, and F. Messud-Petit. 2002. Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins. J. Virol. 76:2912-2923.
20. Hanson, D., and D. G. Diven. 2003. Molluscum contagiosum. Dermatol. Online J. 9:2.
21. Hinthong, O., X. L. Jin, and J. L. Shisler. 2008. Characterization of wild-type and mutant vaccinia virus M2L proteins' abilities to localize to the endoplasmic reticulum and to inhibit NF-kappaB activation during infection. Virology 373:248-262.
22. Huang,J., Q.Huang, X.Zhou, M.M.Shen, A.Yen, S.X.Yu, G.Dong, K.Qu, P. Huang, E. M. Anderson, S. Daniel-Issakani, R. M. Buller, D. G. Payan, and H. H. Lu. 2004. The poxvirus p28 virulence factor is an E3 ubiquitin ligase. J. Biol. Chem. 279:54110-54116.
23. Jensen, O. N., T. Houthaeve, A. Shevchenko, S. Cudmore, T. Ashford, M. Mann, G. Griffiths, and J. Krijnse Locker. 1996. Identification of the major membrane and core proteins of vaccinia virus by two-dimensional electrophoresis. J. Virol. 70:7485-7497.
24. Johnston, J. B., and G. McFadden. 2003. Poxvirus immunomodulatory strategies: current perspectives. J. Virol. 77:6093-6100.
25. Kanagasabaphy, P., G. J. Morgan, and F. E. Davies. 2007. Proteasome inhibition and multiple myeloma. Curr. Opin. Investig. Drugs 8:447-451.
26. Katsafanas, G. C., and B. Moss. 2007. Colocalization of transcription and translation within cytoplasmic poxvirus factories coordinates viral expression and subjugates host functions. Cell Host Microbe 2:221-228.
27. Kile, J. C., A. T. Fleischauer, B. Beard, M. J. Kuehnert, R. S. Kanwal, P. Pontones, H. J. Messersmith, R. Teclaw, K. L. Karem, Z. H. Braden, I. Damon, A. S. Khan, and M. Fischer. 2005. Transmission of monkeypox among persons exposed to infected prairie dogs in Indiana in 2003. Arch. Pediatr. Adolesc. Med. 159:1022-1025.
28. Kirkpatrick, D. S., C. Denison, and S. P. Gygi. 2005. Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nat. Cell Biol. 7:750-757.
29. Lee, D. H., and A. L. Goldberg. 1998. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8:397-403.
30. Leite, J. A., B. P. Drumond, G. S. Trindade, Z. I. Lobato, F. G. da Fonseca, S. J. dos, M. C. Madureira, M. I. Guedes, J. M. Ferreira, C. A. Bonjardim, P. C. Ferreira, and E. G. Kroon. 2005. Passatempo virus, a vaccinia virus strain, Brazil. Emerg. Infect. Dis. 11:1935-1938.
31. Liu, J., L. Wei, T. Jiang, L. Shi, and J. Wang. 2007. Reduction of infectious bursal disease virus replication in cultured cells by proteasome inhibitors. Virus Genes 35:719-727.
32. Mansouri, M., E. Bartee, K. Gouveia, B. T. Hovey Nerenberg, J. Barrett, L. Thomas, G. Thomas, G. McFadden, and K. Fruh. 2003. The PHD/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4. J. Virol. 77:1427-1440.
33. Marris, E. 2007. Dramatic rescue relieves rare case of smallpox infection. Nat. Med. 13:517.
34. Mercer, A. A., S. B. Fleming, and N. Ueda. 2005. F-box-like domains are present in most poxvirus ankyrin repeat proteins. Virus Genes 31:127-133.
35. Moss, B. 2001. Poxviridae: the viruses and their replication, 4th ed., vol. 2. Lippincott Williams and Wilkins, Philadelphia, PA.
36. Myung, J., K. B. Kim, and C. M. Crews. 2001. The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev. 21:245-273.
37. Nerenberg, B. T., J. Taylor, E. Bartee, K. Gouveia, M. Barry, and K. Fruh. 2005. The poxviral RING protein p28 is a ubiquitin ligase that targets ubiquitin to viral replication factories. J. Virol. 79:597-601.
38. Neyts, J., P. Leyssen, E. Verbeken, and E. De Clercq. 2004. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother. 48:2267-2273.
39. Neznanov, N., E. M. Dragunsky, K. M. Chumakov, L. Neznanova, R. C. Wek, A. V. Gudkov, and A. K. Banerjee. 2008. Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication. PLoS ONE 3:e1887.
40. Nijhawan, D., M. Fang, E. Traer, Q. Zhong, W. Gao, F. Du, and X. Wang. 2003. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 17:1475-1486.
41. Nitsche, A., A. Kurth, and G. Pauli. 2007. Viremia in human Cowpox virus infection. J. Clin. Virol. 40:160-162.
42. Parker, S., A. Nuara, R. M. Buller, and D. A. Schultz. 2007. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2:17-34.
43. Pedersen, K., E. J. Snijder, S. Schleich, N. Roos, G. Griffiths, and J. K Locker. 2000. Characterization of vaccinia virus intracellular cores: implications for viral uncoating and core structure. J. Virol. 74:3525-3536.
44. Pickart, C. M. 2001. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70:503-533.
45. Pickart, C. M., and D. Fushman. 2004. Polyubiquitin chains: polymeric protein signals. Curr. Opin. Chem. Biol. 8:610-616.
46. Prosch, S., C. Priemer, C. Hoflich, C. Liebenthaf, N. Babel, D. H. Kruger, and H. D. Volk. 2003. Proteasome inhibitors: a novel tool to suppress human cytomegalovirus replication and virus-induced immune modulation. Antivir. Ther. 8:555-567.
47. Quenelle, D. C., R. M. Buller, S. Parker, K. A. Keith, D. E. Hruby, R. Jordan, and E. R. Kern. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51:689-695.
48. Resch, W., K. K. Hixson, R. J. Moore, M. S. Lipton, and B. Moss. 2007. Protein composition of the vaccinia virus mature virion. Virology 358:233-247.
49. Roccaro, A. M., A. Vacca, and D. Ribatti. 2006. Bortezomib in the treatment of cancer. Recent Patents Anticancer Drug Discov. 1:397-403.
50. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: alaboratorymanual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
51. Schang, L. M. 2002. Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother. 50:779-792.
52. Schubert, U., D. E. Ott, E. N. Chertova, R. Welker, U. Tessmer, M. F. Princiotta, J. R. Bennink, H. G. Krausslich, and J. W. Yewdell. 2000. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. USA 97:13057-13062.
53. Seet, B. T., J. B. Johnston, C. R. Brunetti, J. W. Barrett, H. Everett, C. Cameron, J. Sypula, S. H. Nazarian, A. Lucas, and G. McFadden. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
54. Shackelford, J., and J. S. Pagano. 2005. Targeting of host-cell ubiquitin pathways by viruses. Essays Biochem. 41:139-156.
55. Si, X., G. Gao, J. Wong, Y. Wang, J. Zhang, and H. Luo. 2008. Ubiquitination is required for effective replication of coxsackievirus B3. PLoS ONE 3:e2585.
56. Smith, G. L., and M. Law. 2004. The exit of vaccinia virus from infected cells. Virus Res. 106:189-197.
57. Smith, G. L., and G. McFadden. 2002. Smallpox: anything to declare? Nat. Rev. Immunol. 2:521-527.
58. Smith, G. L., A. Vanderplasschen, and M. Law. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83:2915-2931.
59. Sonnberg, S., B. T. Seet, T. Pawson, S. B. Fleming, and A. A. Mercer. 2008. Poxvirus ankyrin repeat proteins are a unique class of F-box proteins that associate with cellular SCF1 ubiquitin ligase complexes. Proc. Natl. Acad. Sci. USA 105:10955-10960.
60. Sperling, K. M., A. Schwantes, B. S. Schnierle, and G. Sutter. 2008. The highly conserved orthopoxvirus 68k ankyrin-like protein is part of a cellular SCF ubiquitin ligase complex. Virology 374:234-239.
61. Takahashi, T., M. Oie, and Y. Ichihashi. 1994. N-terminal amino acid sequences of vaccinia virus structural proteins. Virology 202:844-852.
62. Tseng, M., N. Palaniyar, W. Zhang, and D. H. Evans. 1999. DNA binding and aggregation properties of the vaccinia virus I3L gene product. J. Biol. Chem. 274:21637-21644.
63. Tulman, E. R., C. L. Afonso, Z. Lu, L. Zsak, G. F. Kutish, and D. L. Rock. 2004. The genome of canarypox virus. J. Virol. 78:353-366.
64. van Buuren, N., B. Couturier, Y. Xiong, and M. Barry. 2008. Ectromelia virus encodes a novel family of F-box proteins that interact with the SCF complex. J. Virol. 82:9917-9927.
65. Weissman, A. M. 2001. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2:169-178.
66. Welsch, S., L. Doglio, S. Schleich, and J. Krijnse Locker. 2003. The vaccinia virus I3L gene product is localized to a complex endoplasmic reticulum-associ- ated structure that contains the viral parental DNA. J. Virol. 77:6014-6028.
67. Wilton, B. A., S. Campbell, N. Van Buuren, R. Garneau, M. Furukawa, Y. Xiong, and M. Barry. 2008. Ectromelia virus BTB/kelch proteins, EVM150 and EVM167, interact with cullin-3-based ubiquitin ligases. Virology 374: 82-99.
68. Wolffe, E. J., A. S. Weisberg, and B. Moss. 1998. Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-contain- ing microvilli and cell-to-cell virus spread. Virology 244:20-26.
69. Yang, Y., J. Kitagaki, R. M. Dai, Y. C. Tsai, K. L. Lorick, R. L. Ludwig, S. A. Pierre, J. P. Jensen, I. V. Davydov, P. Oberoi, C. C. Li, J. H. Kenten, J. A. Beutler, K. H. Vousden, and A. M. Weissman. 2007. Inhibitors of ubiquitin- activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67:9472-9481.
70. Yao, X. D., and D. H. Evans. 2004. Construction of recombinant vaccinia viruses using leporipoxvirus-catalyzed recombination and reactivation of orthopoxvirus DNA. Methods Mol. Biol. 269:51-64.
71. Yoder, J. D., T. S. Chen, C. R. Gagnier, S. Vemulapalli, C. S. Maier, and D. E. Hruby. 2006. Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins. Virol. J. 3:10.
72. Yu, G. Y., and M. M. Lai. 2005. The ubiquitin-proteasome system facilitates the transfer of murine coronavirus from endosome to cytoplasm during virus entry. J. Virol. 79:644-648.